Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis

详细信息    查看全文

• 作者：Xiaoling Cai ; Wenjia Yang ; Lingli Zhou ; Simin Zhang ; Xueyao Han ; Linong Ji
• 关键词：DPP ; 4 inhibitors ; α ; Glucosidase inhibitors ; Type 2 diabetes mellitus ; HbA1c ; HOMA ; β
• 刊名：Endocrine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：50
• 期：3
• 页码：590-597
• 全文大小：847 KB
• 参考文献：1.J.F. Habener, Insulinotropic glucagon-like peptides, in Diabetes Mellitus: A Fundamental and Clinical Text, 2nd edn., ed. by D. LeRoith, S.I. Taylor, J.M. Olefsky (Lippincott Williams & Wilkins, Philadelphia, 2000)
  2.K. Aaboe, T. Krarup, S. Madsbad, J.J. Holst, GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes. Metab. 10, 994-003 (2008)CrossRef PubMed
  3.A.J. Garber, Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care 34(Suppl 2), S258–S263 (2011)PubMedCentral CrossRef PubMed
  4.F.A. Van de Laar, P.L. Lucassen, R.P. Akkermans, E.H. Van de Lisdonk, G.E. Rutten, C. Van Weel, Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2, CD003639 (2005)PubMed
  5.A. Karasik, P. Aschner, H. Katzeff, M.J. Davies, P.P. Stein, Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr. Med. Res. Opin. 24, 489-96 (2008)CrossRef PubMed
  6.A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, H.J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1-2 (1996)CrossRef PubMed
  7.A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. G?tzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6, e1000100 (2009)PubMedCentral CrossRef PubMed
  8.Y. Seino, T. Fujita, S. Hiroi, M. Hirayama, K. Kaku, Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr. Med. Res. Opin. 9, 1781-792 (2011)CrossRef
  9.R. Kawamori, N. Inagaki, E. Araki, H. Watada, N. Hayashi, Y. Horie, A. Sarashina, Y. Gong, M. von Eynatten, H.J. Woerle, K.A. Dugi, Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes. Metab. 14, 348-57 (2012)CrossRef PubMed
  10.K. Nakamura, H. Oe, H. Kihara, K. Shimada, S. Fukuda, K. Watanabe, T. Takagi, K. Yunoki, T. Miyoshi, K. Hirata, J. Yoshikawa, H. Ito, DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc. Diabetol. 13, 110-20 (2014)PubMedCentral CrossRef PubMed
  11.Y. Iwamoto, N. Tajima, T. Kadowaki, K. Nonaka, T. Taniguchi, M. Nishii, J.M. Amatruda, J.C. Arjona Ferreira, Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes. Metab. 12, 613-22 (2010)CrossRef PubMed
  12.C. Pan, W. Yang, J.P. Barona, Y. Wang, M. Niggli, P. Mohideen, Y. Wang, J.E. Foley, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Med. 25, 435-41 (2008)CrossRef
  13.Y. Iwamoto, A. Kashiwagi, N. Yamada, S. Terao, N. Mimori, M. Suzuki, H. Tachibana, Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12, 700-08 (2010)PubMedCentral CrossRef PubMed
  14.K. Okada, H. Yagyu, K. Kotani, H. Yamazaki, K. Ozaki, M. Takahashi, S. Nagashima, J. Osuga, S. Ishibashi, Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus. Endocr. J. 60(7), 913-22 (2013)CrossRef PubMed
  15.A. Mikada, T. Narita, H. Yokoyama, R. Yamashita, Y. Horikawa, K. Tsukiyama, Y. Yamada, Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. “the MASTER randomized, controlled trial- Diabetes Res. Clin. Pract. 106(3), 538-47 (2014)CrossRef PubMed
  16.K. Kobayashi, H. Yokoh, Y. Sato, M. Takemoto, D. Uchida, A. Kanatsuka, N. Kuribayashi, T. Terano, N. Hashimoto, K. Sakurai, H. Hanaoka, K. Ishikawa, S. Onishi, K. Yokote, SUCCESS Study Group, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes. Metab. 16(8), 761-65 (2014)CrossRef PubMed
  17.X. Cai, X. Han, Y. Luo, L. Ji, Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PLoS ONE 8(11), e79421 (2013)PubMedCentral CrossR
• 作者单位：Xiaoling Cai (1)
  Wenjia Yang (1)
  Lingli Zhou (1)
  Simin Zhang (1)
  Xueyao Han (1)
  Linong Ji (1)
  
  1. Endocrine and Metabolism Department, Peking University People’s Hospital, Beijing, 100044, China
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

The aim of this study is to compare the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitor treatment with α-glucosidase inhibitor (AGI) treatment in patients with type 2 diabetes through a meta-analysis. Studies were identified by a literature search of Medline, Embase, and others from the time that recording commenced until December 2014. The meta-analysis was performed by computing the weighted mean difference (WMD) and 95 % confidence interval (CI) for a change from baseline to the study endpoint for DPP-4 inhibitors versus AGIs. Nine randomized controlled trial were judged to be appropriate for inclusion in the meta-analysis. One thousand and forty-six patients were treated with a DPP-4 inhibitor, while 929 patients were treated with AGI treatment; the groups had a comparable baseline body mass index of 25.5 ± 1.3 kg/m2 and mean baseline HbA_1c of 7.83 ± 0.53 %. Treatment with DPP-4 inhibitors led to a significantly greater change from baseline in the HbA_1c levels (WMD ?.30 %; 95 % CI ?.47 to ?.13 %, p < 0.001) and fasting plasma glucose levels (WMD ?.50 mmol/L; 95 % CI ?.89 to ?.11 mmol/L, p = 0.01) compared with AGI treatment. Compared with AGIs, treatment with DPP-4 inhibitors was associated with a significantly greater increase in the weight change from baseline (WMD 0.89 kg; 95 % CI 0.53-.25, p < 0.001). Treatment with DPP-4 inhibitors was associated with a significantly greater increase in the fasting insulin level from baseline (WMD 0.63 μU/mL; 95 % CI 0.35-.90 μU/mL, p < 0.001). DPP-4 inhibitors significantly improved homeostatic model assessment for β-cell function in type 2 diabetes patients compared with AGI treatment (WMD 5.43; 95 % CI 1.01-.85, p = 0.02). DPP-4 inhibitors were associated with a significantly greater decrease in the cholesterol (CHO) level (WMD ?.19 mmol/L; 95 % CI ?.19 to ?.19 mmol/L, p < 0.001) and a significantly greater decrease in the low-density lipoprotein cholesterol (LDL-C) level (WMD ?.16 mmol/L; 95 % CI ?.26 to ?.05 mmol/L, p = 0.003). Compared with AGIs (813 participants), treatment with DPP-4 inhibitors (1031 participants) was associated with a significantly lower incidence of drug-related adverse event (OR 0.48; 95 % CI 0.36-.64, p < 0.0001). The efficacy of glucose control and improvement of β-cell function, as well as total CHO and LDL-C decreases, in DPP-4 inhibitor treatment were superior to those with AGI treatment, and there was a lower incidence of drug-related AE. Keywords DPP-4 inhibitors α-Glucosidase inhibitors Type 2 diabetes mellitus HbA1c HOMA-β